Novartis Remibrutinib, a High-Efficacy Oral BTK Inhibitor, Significantly Reduces Relapse Rates and Shows Favorable Safety Profile in Phase III RMS Trials
Phase 3positiveremibrutinibPositive
AI Analysis
Summary
Novartis announced positive Phase III topline results for remibrutinib (REMODEL-1/-2 trials) in relapsing multiple sclerosis, demonstrating significant reduction in relapse rates and a favorable safety profile.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials
Importance:8/10
Sentiment:
0.85
Phase 3BTK inhibitormultiple sclerosispositive dataoral therapy
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on September 1, 2026 8:09 PM